270 related articles for article (PubMed ID: 16928753)
1. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction.
Barth H; Schnober EK; Zhang F; Linhardt RJ; Depla E; Boson B; Cosset FL; Patel AH; Blum HE; Baumert TF
J Virol; 2006 Nov; 80(21):10579-90. PubMed ID: 16928753
[TBL] [Abstract][Full Text] [Related]
2. Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans.
Xu Y; Martinez P; Séron K; Luo G; Allain F; Dubuisson J; Belouzard S
J Virol; 2015 Apr; 89(7):3846-58. PubMed ID: 25609801
[TBL] [Abstract][Full Text] [Related]
3. Specific interaction of the envelope glycoproteins E1 and E2 with liver heparan sulfate involved in the tissue tropismatic infection by hepatitis C virus.
Kobayashi F; Yamada S; Taguwa S; Kataoka C; Naito S; Hama Y; Tani H; Matsuura Y; Sugahara K
Glycoconj J; 2012 May; 29(4):211-20. PubMed ID: 22660965
[TBL] [Abstract][Full Text] [Related]
4. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate.
Barth H; Schafer C; Adah MI; Zhang F; Linhardt RJ; Toyoda H; Kinoshita-Toyoda A; Toida T; Van Kuppevelt TH; Depla E; Von Weizsacker F; Blum HE; Baumert TF
J Biol Chem; 2003 Oct; 278(42):41003-12. PubMed ID: 12867431
[TBL] [Abstract][Full Text] [Related]
5. A potential role of the heparan sulfate in the hepatitis C virus attachment.
Heo TH
Acta Virol; 2008; 52(1):7-15. PubMed ID: 18459830
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.
Steinmann D; Barth H; Gissler B; Schürmann P; Adah MI; Gerlach JT; Pape GR; Depla E; Jacobs D; Maertens G; Patel AH; Inchauspé G; Liang TJ; Blum HE; Baumert TF
J Virol; 2004 Sep; 78(17):9030-40. PubMed ID: 15308699
[TBL] [Abstract][Full Text] [Related]
7. Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins.
Koutsoudakis G; Dragun J; Pérez-Del-Pulgar S; Coto-Llerena M; Mensa L; Crespo G; González P; Navasa M; Forns X
PLoS One; 2012; 7(12):e52651. PubMed ID: 23300734
[TBL] [Abstract][Full Text] [Related]
8. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.
Bose M; Mullick R; Das S; Das S; Karande AA
Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of hepatitis B and C virus envelope glycoproteins.
Jeulin H; Velay A; Murray J; Schvoerer E
World J Gastroenterol; 2013 Feb; 19(5):654-64. PubMed ID: 23429668
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF
Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838
[TBL] [Abstract][Full Text] [Related]
11. An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry.
McCaffrey K; Boo I; Owczarek CM; Hardy MP; Perugini MA; Fabri L; Scotney P; Poumbourios P; Drummer HE
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031364
[TBL] [Abstract][Full Text] [Related]
12. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding.
Triyatni M; Vergalla J; Davis AR; Hadlock KG; Foung SK; Liang TJ
Virology; 2002 Jun; 298(1):124-32. PubMed ID: 12093180
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions.
Keck ZY; Op De Beeck A; Hadlock KG; Xia J; Li TK; Dubuisson J; Foung SK
J Virol; 2004 Sep; 78(17):9224-32. PubMed ID: 15308717
[TBL] [Abstract][Full Text] [Related]
14. Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients.
Douam F; Bobay LM; Maurin G; Fresquet J; Calland N; Maisse C; Durand T; Cosset FL; Féray C; Lavillette D
J Virol; 2016 Jan; 90(2):992-1008. PubMed ID: 26537674
[TBL] [Abstract][Full Text] [Related]
15. Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis.
Gopal R; Jackson K; Tzarum N; Kong L; Ettenger A; Guest J; Pfaff JM; Barnes T; Honda A; Giang E; Davidson E; Wilson IA; Doranz BJ; Law M
PLoS Pathog; 2017 Dec; 13(12):e1006735. PubMed ID: 29253863
[TBL] [Abstract][Full Text] [Related]
16. Ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape.
Zhao Y; Ren Y; Zhang X; Zhao P; Tao W; Zhong J; Li Q; Zhang XL
J Immunol; 2014 Jul; 193(2):783-96. PubMed ID: 24928988
[TBL] [Abstract][Full Text] [Related]
17. Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry.
Prentoe J; Bukh J
Front Immunol; 2018; 9():2146. PubMed ID: 30319614
[TBL] [Abstract][Full Text] [Related]
18. Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.
Haddad JG; Rouillé Y; Hanoulle X; Descamps V; Hamze M; Dabboussi F; Baumert TF; Duverlie G; Lavie M; Dubuisson J
J Virol; 2017 Apr; 91(8):. PubMed ID: 28179528
[TBL] [Abstract][Full Text] [Related]
19. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
[TBL] [Abstract][Full Text] [Related]
20. Human herpesvirus 8 envelope-associated glycoprotein B interacts with heparan sulfate-like moieties.
Akula SM; Pramod NP; Wang FZ; Chandran B
Virology; 2001 Jun; 284(2):235-49. PubMed ID: 11384223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
